Connect with us


Newsom Neutered – Repeals California’s Orwellian ‘COVID Misinformation’ Law

Newsom Neutered – Repeals California’s Orwellian ‘COVID Misinformation’ Law

Authored by Brad Jones via The Epoch Times,

California Gov. Gavin…



Newsom Neutered - Repeals California's Orwellian 'COVID Misinformation' Law

Authored by Brad Jones via The Epoch Times,

California Gov. Gavin Newsom has signed legislation to repeal a portion of the state’s COVID-19 “misinformation” and “disinformation” law intended to punish doctors who refused to comply with the government’s narrative on masks, vaccines, and treatments during the pandemic.

On Sept. 30, the governor signed Senate Bill 815 repealing provisions in the law—under Assembly Bill 2098—that “expressly designate the dissemination of misinformation or disinformation related to COVID-19 as unprofessional conduct,” according to an analysis by the bill’s author, Assemblyman Richard Roth (D-Riverside).

A year ago when Mr. Newsom signed AB 2098, introduced by Assemblyman Evan Low (D-Campbell) and co-authored by then-Sen. Richard Pan (D-Sacramento) into law, he warned of a “chilling effect” other potential laws could have on the freedom of physicians and surgeons to effectively talk to their patients about the risks and benefits of treatments for COVID-19 but said he was “confident” the bill was “narrowly tailored” to apply only to egregious instances in which a doctor was acting with malicious intent or clearly deviating from the “required standard of care.”

Just days later, the law, which vaguely defined “misinformation and disinformation” as “unprofessional conduct,” was challenged in court. The law defined disinformation as “misinformation that the licensee deliberately disseminated with malicious intent or an intent to mislead” and misinformation as “false information that is contradicted by contemporary scientific consensus contrary to the standard of care.”

Dr. Aaron Kheriaty, a former professor of psychiatry and human behavior at the University of California–Irvine’s School of Medicine and director of the medical ethics program, was fired on Dec. 16, 2021, for refusing to get a COVID-19 vaccine, claiming he had natural immunity after contracting the illness and recovering from it.

He and four other doctors—Tracy Hoeg, Ram Duriseti, Pete Mazolewski, and Azadeh Khatibi—sued Mr. Newsom, state Attorney General Rob Bonta, and several administrators at the Medical Board of California.

“We were being discriminated against because we had a form of immunity that was equally good, in fact superior … compared to vaccine immunity,” Dr. Kheriaty told The Epoch Times.

“People with vaccine immunity were allowed on campus, and I was not.”

Judge William Shubb of the U.S. District Court for the Eastern District of California granted a preliminary injunction blocking the state from enforcing AB 2098, ruling that the statute’s “unclear phrasing and structure” could have a “chilling effect.”

Dr. Kheriaty said he’s glad SB 815 has negated the “misinformation” and “disinformation” provisions of AB 2098.

“This is a good victory, but we can’t rest on our laurels,” he said.

“We’ve got to be very vigilant because people who want to take control over medicine and intervene in the doctor-patient relationship are going to keep trying to find other angles.”

Dr. Kheriaty suspects the governor and state legislators realized when the preliminary injunction was granted that the court would most likely rule against AB 2098 and ultimately declare it unconstitutional.

“So, rather than getting slapped down by the court in ways that would have probably made the newspapers, they decided to quietly shuffle the law off the stage as a kind of embarrassment and hope that no one really noticed,” he said.

Attorneys for the five doctors have filed a motion for a summary judgment from the court.

“We would like to see the government lawyers have to argue in court in our favor … because the law has been struck down,” Dr. Kheriaty said.

“We would like to hear them publicly say that in court.”

Dr. Kheriaty said the case shows that because “scientific consensus” during the pandemic evolved quickly, doctors were punished for simply being ahead of the curve and expressing or endorsing ideas the rest of the medical community had not yet caught up with because they weren’t paying as close attention to the available research.

While AB 2098 attempted “to fixate a particular scientific consensus,” the court found scientific consensus to be an ill-defined legal concept, he said.

“The fact that this law was struck down is obviously meaningful to me … but it’s also concerning that this law was passed in the first place,” he said.

The U.S. Centers for Disease Control and Prevention (CDC) has since indicated that it should not discriminate between vaccinated and unvaccinated because vaccines don’t stop infection and transmission.

Natural immunity is “robust, durable, and long-lasting,” Dr. Kheriaty said. “So, I guess I lost my job for being nine months ahead of the curve.”

Mixing Politics With Science

In his book, “The New Abnormal: The Rise of the Biomedical Security State,” Dr. Kheriaty examines the “age-old problem” of mixing politics with science.

The book, he said, is about the biomedical security state melding an increasingly militarized public health apparatus with the use of digital technologies of surveillance and control, such as vaccine passports, and backing those two elements with police powers of the state and the declared state of emergency which allowed governors and the president to accrue additional extra-constitutional powers and “wield tremendous authority” effectively “micromanaging the lives of citizens.”

“Especially today, when science has a certain authority or prestige, political power wants to commandeer and weaponize science to achieve its aims, and that’s what you saw during the pandemic,” he said. “It’s what I call scientism.”

Scientism, he explained, tries to monopolize science and claim that it is the only valid form of knowledge and then appoints its preferred “so-called experts” to speak in the name of science.

“That has nothing to do with science. That’s a power move. In fact, it’s a totalitarian move because that’s what totalitarian regimes do: They monopolize what counts as knowledge and rationality, and they exclude anyone who doesn’t endorse their ideology,” Dr. Kheriaty said.

“That was done with science during the pandemic. Science was weaponized.”

Scientism is “totally antithetical to science,” which relies on open-ended inquiry, hypothesis, conjecture and debate, evidence, reputation and the willingness to change one’s mind, he said. “And so, trying to fix a particular ‘consensus’ as unassailable completely contradicts the whole ethos of scientific investigation. Science advances precisely by challenging conventional thinking or consensus or what we take to be common sense.”

Prior to the lawsuit, Dr. Kheriaty challenged the University of California system’s vaccine policies in an opinion article published in the Wall Street Journal “just to try to get a conversation going,” he said.

But the UC Irvine authorities weren’t interested in discussion or debate and fired him for allegedly refusing to comply with the vaccine mandate after they twice declined a medical exemption signed by his physician and accused him of unprofessional conduct.

“I was a threat,” he said. “So, it was easier just to shut down the debate.”

The state then used him as an example to send a message to other doctors who dared to step out of line, he suggested.

“You don’t have to fire too many people before it has a real chilling effect on everyone else,” he said.

“Obviously, other people could look at what happened to me, and it was very clear: ‘OK, this is one issue that you just don’t touch. You don’t open your mouth and speak your mind unless it’s to endorse the position that the university wants to take.’”

Dr. Kheriaty now runs a private practice in Orange County. He is also a scholar at the Ethics and Public Policy Center, a Judeo-Christian based group in Washington, D.C., the chief of medical ethics at The Unity Project, a non-profit medical freedom and parental rights group, and the Brownstone Institute has supported his work in public health.

“So, I’m very happy,” he said. “I’ve landed on my feet. I don't really have a desire to go back to the university.”

Dr. Kheriaty is also a plaintiff in the Missouri v. Biden case, alleging the federal government violated the First Amendment by pressuring social media companies to censor disfavored speech.

'Legislative Power Grab'

Dr. Robert Malone, who helped invent the technology used in the Moderna and Pfizer vaccines, told The Epoch Times on Oct. 2 that AB 2098 would not likely have survived a legal challenge and is “an embarrassment for Newsom” and his presidential ambitions.

Dr. Malone called AB 2098 a “legislative power grab” from the state medical board to the legislature and criticized state lawmakers for interfering in the practice of medicine.

To have COVID-specific legislation on regulating medical standards is “bizarre” in the first place because there is already “perfectly adequate” legislation regulating medical standards, he said.

He said Mr. Low’s Sept. 12 statement that the “update” will still hold doctors accountable suggests the new law is “a wolf in sheep’s clothing,” he said.

“Fortunately, with this update, the Medical Board of California will continue to maintain the authority to hold medical licensees accountable for deviating from the standard of care and misinforming their patients about COVID-19 treatments,” Mr. Low said in the statement emailed to The Epoch Times.

A doctor with an adverse finding or even a pending investigation against their medical license cannot transfer their licenses to another state, so physicians in this situation are forced to decide whether to leave the state before it has an opportunity to impose an action against their license or run the risk of losing it, “which would make it impossible for them to leave the state,” said Dr. Malone.

“Independent thinkers—the very people that you most want to have medicine—are being run out by the state legislative policies,” he said. “It means that people with no qualifications to practice medicine are mandating how medicine must be practiced directly.

Dr. Malone, the chief medical officer at The Unity Project, is known for expressing concerns about the possibility of immune imprinting. He claimed vaccines provide poor protection over time, with some indications the shielding turns negative.

The “politicization of medicine,” during the pandemic years was “bad medicine,” he said, noting that recent reports about myocarditis are “stunning.”

For more than a year-and-a-half, news reports have documented that the CDC “has been withholding critical information from the medical community relating to COVID-19 vaccines and their safety, Dr. Malone said.

Laura Sextro, CEO of The Unity Project, told the Epoch Times there was no need for SB 815 or AB 2098.

“The writing is on the wall,” she said. “There’s a temporary injunction right now against AB 2098, and I think the authors of this terrible legislation knew that they had to do something to modify this because it’s so horrendous.”

Ms. Sextro said a doctor who owns an urgent care clinic with seven practitioners in California told her on Oct. 2 the clinic would be shuttered because of legislation like AB 2098 and SB 815.

“They’ve made the decision to close the clinic,” she said.

“I think that bills like AB 2098 are actually designed to penalize the sole proprietor doctors—the single-practice doctors who are not associated with … big box medical groups,” she said.

Other Legal Challenges

AB 2098 has since met other legal challenges, including complaints from Democratic presidential candidate Robert F. Kennedy Jr. and the American Civil Liberties Union and two California doctors, Dr. Mark McDonald and Dr. Jeff Barke.

Shubb's ruling runs contrary to Judge Fred W. Slaughter’s earlier decision to deny a preliminary injunction in the case involving Dr. Barke and Dr. McDonald, who sued the medical board, Mr. Newsom, and AG Bonta in the U.S. District Court for the Central District of California last year. The lawsuit, which is still pending, asked the court to declare AB 2098 unconstitutional and sought a preliminary injunction to prevent its enforcement.

Dr. Simone Gold, a Beverly Hills physician who founded America’s Frontline Doctors, called AB 2098 an “unconstitutional, Orwellian gag-order,” that attempts to mandate a new and undefined standard known as ‘contemporary scientific consensus’ and illegally suppress dissenting professional medical opinions.

Eric Hintz, legislative director for Assemblyman Bill Essayli (R-Corona) told The Epoch Times several Republicans voted against SB 815 because they knew the Democratic majority would pass it to remove the “misinformation” and “disinformation” provisions in AB 2098 and because Republicans wanted to voice opposition to fee increases for medical licenses in the state.

The bill increases medical license fees for all physicians by $288, from $863 to $1,151.

“So, I think that’s the reason why a lot of Republicans decided to vote against it,” Mr. Hintz said.

The bill would also extend the regulatory powers of the medical board by two more years from a Jan. 1, 2026, sunset clause to Jan. 1, 2028.

“That would be another reason why someone might oppose the bill,” he said.

Tyler Durden Wed, 10/04/2023 - 20:20

Read More

Continue Reading


Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…



Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading